Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- DSP Launches Latuda in Canada
September 19, 2012
- Eli Lilly Japan Applies for Strattera Oral Solution
September 19, 2012
- 60% of Sales to Come from Specialty Field, Oncology by 2017: President Mitani of Novartis Pharma
September 19, 2012
- Janssen Pharmaceutical Discontinues PII Study for Atopic Dermatitis Treatment in Japan
September 19, 2012
- Eisai to Push Efficacy of Careram in Combination with MTX, Low Drug Costs
September 19, 2012
- MTPC, Daiichi Sankyo Conduct Largest Ever Copromotion for Tenelia, Aiming for Top Position in Diabetes Market with SGLT-2 Inhibitor
September 19, 2012
- Teva Appoints Itzhak Krinsky as Chairman for Japan, South Korea
September 18, 2012
- Chugai Provides All-Case PMS Data via iPad, Beginning with Avastin
September 18, 2012
- Kaketsuken Starts PIII Trial for Cell-Culture-Based New-Type Influenza Vaccine
September 18, 2012
- Astellas Launches Enzalutamide in the US
September 18, 2012
- 100,000 Registrations Expected by End of Year on Japan Vaccine’s Mobile Phone Vaccination Website
September 18, 2012
- Kyowa Kirin to Return Rights for Busulfex in Japan and Asia to Otsuka
September 18, 2012
- Detailing with iPad Rapidly Increases, Up 21.6 Points to 48.8%: Doctor Survey
September 14, 2012
- JT Sees Silver Lining in Pharmaceutical Biz 25 Yrs after Market Entry; 1st Approval Obtained for Proprietary Drug
September 14, 2012
- Eisai Ties up with US NPO to Support Vaccine Development for Tropical Diseases
September 14, 2012
- Eisai Launches Next Mainstay Product in Europe; Antiepileptic Perampanel
September 14, 2012
- MTPC Files for Additional Indication of Chronic Atrial Fibrillation for Maintate
September 14, 2012
- Bayer Yakuhin Granted Priority Review for NDA for Regorafenib
September 13, 2012
- Takeda Completes New Russian Factory, Full-Scale Operation Scheduled in 2014
September 13, 2012
- FDA Accepts Resubmission of NDA for Once-Monthly Aripiprazole Injection: Otsuka
September 13, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…